Sign in or create an account to add this stock to your watchlist.
About G1 Therapeutics (NASDAQ:GTHX)
G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel small molecule therapeutics for the treatment of patients with cancer in the United States. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase 1b/2a clinical trials for patients with small cell lung cancer, as well as Phase 2 clinical trial for patients with first-/second-/third-line metastatic triple-negative breast cancer; G1T38, an oral CDK4/6 inhibitor that is Phase 1b/2a clinical trials for the treatment of breast cancer; and G1T48, an oral selective estrogen receptor degrader, which is in preclinical development. The company was founded in 2008 and is headquartered in Research Triangle Park, North Carolina.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:GTHX
CUSIPN/A
Phone919-213-9835
Debt
Debt-to-Equity RatioN/A
Current Ratio15.61
Quick Ratio15.61
Price-To-Earnings
Trailing P/E Ratio-14.33
Forward P/E Ratio-19.24
P/E GrowthN/A
Sales & Book Value
Annual Sales$520,000.00
Price / Sales3,217.81
Cash FlowN/A
Price / CashN/A
Book Value$5.60 per share
Price / Book9.14
Profitability
EPS (Most Recent Fiscal Year)($3.57)
Net Income$-60,120,000.00
Net MarginsN/A
Return on Equity-53.55%
Return on Assets-49.18%
Miscellaneous
Employees44
Outstanding Shares32,700,000
G1 Therapeutics (NASDAQ:GTHX) Frequently Asked Questions
What is G1 Therapeutics' stock symbol?
G1 Therapeutics trades on the NASDAQ under the ticker symbol "GTHX."
How were G1 Therapeutics' earnings last quarter?
G1 Therapeutics Inc (NASDAQ:GTHX) posted its quarterly earnings data on Thursday, May, 3rd. The company reported ($0.70) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.63) by $0.07. View G1 Therapeutics' Earnings History.
When is G1 Therapeutics' next earnings date?
What price target have analysts set for GTHX?
5 analysts have issued 12 month target prices for G1 Therapeutics' stock. Their forecasts range from $31.00 to $60.00. On average, they expect G1 Therapeutics' stock price to reach $41.80 in the next year. View Analyst Ratings for G1 Therapeutics.
What are Wall Street analysts saying about G1 Therapeutics stock?
Here are some recent quotes from research analysts about G1 Therapeutics stock:
- 1. According to Zacks Investment Research, "G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It engaged in developing novel, small-molecule therapies which address significant unmet needs in the treatment of cancer. The company's product pipeline consists of CDK4/6, Trilaciclib (G1T28), G1T38 and G1T48. G1 Therapeutics, Inc. is based in Research Triangle Park, NC. " (5/15/2018)
- 2. BTIG Research analysts commented, "On Monday before market open, G1 announced positive topline data from the Phase 2a study of trilaciclib in combination with etoposide + carboplatin for patients with Extensive-stage SCLC (1st Line). We think that the Phase 2a study hit the important safety endpoints and set the company up well for later-line data with SCLC and metastatic Triple Negative Breast Cancer expected during 2H2018. Importantly, mgmt. indicated that they would use the strength of the 1st Line SCLC Phase2a data to begin discussions with regulators, which could accelerate the timeline versus awaiting data from the other studies during 2H2018. We reiterate our Buy rating and raise our PT to $48 from $38 as the topline release de-risks our assumptions around SCLC." (3/7/2018)
- 3. Cowen Inc analysts commented, "G1 Therapeutics reported a Q3 net loss of $16MM and September 30 cash of." (11/8/2017)
Are investors shorting G1 Therapeutics?
G1 Therapeutics saw a drop in short interest in April. As of April 13th, there was short interest totalling 1,241,765 shares, a drop of 32.8% from the March 30th total of 1,847,550 shares. Based on an average daily volume of 164,616 shares, the days-to-cover ratio is presently 7.5 days. Currently, 6.4% of the company's shares are sold short.
Who are some of G1 Therapeutics' key competitors?
Some companies that are related to G1 Therapeutics include Sarepta Therapeutics (SRPT), Ionis Pharmaceuticals (IONS), Catalent (CTLT), GALAPAGOS NV/S (GLPG), Loxo Oncology (LOXO), Agios Pharmaceuticals (AGIO), Dr. Reddy's Laboratories (RDY), United Therapeutics (UTHR), Taro Pharmaceutical Industries (TARO), Hutchison China MediTech (HCM), FibroGen (FGEN), GW Pharmaceuticals (GWPH), Ligand Pharmaceuticals (LGND), Blueprint Medicines (BPMC) and Array Biopharma (ARRY).
Who are G1 Therapeutics' key executives?
G1 Therapeutics' management team includes the folowing people:
- Dr. Mark A. Velleca, CEO, Pres & Director (Age 54)
- Dr. Rajesh K. Malik, Chief Medical Officer (Age 59)
- Mr. Barclay A. Phillips, CFO & Sr. VP of Corp. Devel. (Age 55)
- Ms. Jennifer K. Moses, VP of Fin. & Admin. & Principal Accounting Officer (Age 43)
- Mr. Alexander D. Smith M.S., VP of Technical Operations
When did G1 Therapeutics IPO?
(GTHX) raised $101 million in an initial public offering on Wednesday, May 17th 2017. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Cowen and Company acted as the underwriters for the IPO and Needham & Company and Wedbush PacGrow were co-managers.
Has G1 Therapeutics been receiving favorable news coverage?
Media headlines about GTHX stock have been trending somewhat positive recently, according to Accern. The research group scores the sentiment of media coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. G1 Therapeutics earned a coverage optimism score of 0.02 on Accern's scale. They also gave media headlines about the company an impact score of 46.83 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near future.
Who are G1 Therapeutics' major shareholders?
G1 Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Franklin Resources Inc. (4.00%), BlackRock Inc. (3.92%), Rock Springs Capital Management LP (0.88%), Point72 Asset Management L.P. (0.69%), JPMorgan Chase & Co. (0.68%) and Northern Trust Corp (0.48%). Company insiders that own G1 Therapeutics stock include Clay Thorp, Fredric N Eshelman, Jennifer K Moses, Mark A Velleca, Medimmune Ventures, Inc, Ra Capital Healthcare Fund Lp and Rajesh Malik. View Institutional Ownership Trends for G1 Therapeutics.
Which major investors are selling G1 Therapeutics stock?
GTHX stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Hodges Capital Management Inc. and Victory Capital Management Inc.. Company insiders that have sold G1 Therapeutics company stock in the last year include Clay Thorp, Jennifer K Moses, Mark A Velleca, Medimmune Ventures, Inc and Rajesh Malik. View Insider Buying and Selling for G1 Therapeutics.
Which major investors are buying G1 Therapeutics stock?
GTHX stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., JPMorgan Chase & Co., Northern Trust Corp, Rock Springs Capital Management LP, Point72 Asset Management L.P., Birchview Capital LP, Swiss National Bank and Millennium Management LLC. Company insiders that have bought G1 Therapeutics stock in the last two years include Clay Thorp, Fredric N Eshelman and Ra Capital Healthcare Fund Lp. View Insider Buying and Selling for G1 Therapeutics.
How do I buy shares of G1 Therapeutics?
Shares of GTHX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is G1 Therapeutics' stock price today?
One share of GTHX stock can currently be purchased for approximately $51.17.
How big of a company is G1 Therapeutics?
G1 Therapeutics has a market capitalization of $1.62 billion and generates $520,000.00 in revenue each year. The company earns $-60,120,000.00 in net income (profit) each year or ($3.57) on an earnings per share basis. G1 Therapeutics employs 44 workers across the globe.
How can I contact G1 Therapeutics?
G1 Therapeutics' mailing address is 79 T.W. Alexander Drive 4501 Research Commons Suite 100, Research Triangle Park NC, 27709. The company can be reached via phone at 919-213-9835.
MarketBeat Community Rating for G1 Therapeutics (GTHX)
MarketBeat's community ratings are surveys of what our community members think about G1 Therapeutics and other stocks. Vote "Outperform" if you believe GTHX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GTHX will underperform the S&P 500 over the long term. You may vote once every thirty days.
G1 Therapeutics (NASDAQ:GTHX) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
5 Wall Street analysts have issued ratings and price targets for G1 Therapeutics in the last 12 months. Their average twelve-month price target is $41.80, suggesting that the stock has a possible downside of 18.31%. The high price target for GTHX is $60.00 and the low price target for GTHX is $31.00. There are currently 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $41.80 | $38.20 | $32.80 | $29.75 |
| Price Target Upside: | 18.31% downside | 7.45% upside | 70.66% upside | 33.41% upside |
G1 Therapeutics (NASDAQ:GTHX) Consensus Price Target History
G1 Therapeutics (NASDAQ:GTHX) Analyst Ratings History
Show:
(Data available from 5/24/2016 forward)
G1 Therapeutics (NASDAQ:GTHX) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
G1 Therapeutics (NASDAQ GTHX) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 15.92%
Institutional Ownership Percentage: 60.93%
G1 Therapeutics (NASDAQ GTHX) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 5/23/2018 | Clay Thorp | Major Shareholder | Sell | 37,500 | $51.11 | $1,916,625.00 | |  |
| 5/15/2018 | Mark A Velleca | Insider | Sell | 7,500 | $46.28 | $347,100.00 | | |
| 5/7/2018 | Jennifer K Moses | VP | Sell | 750 | $45.00 | $33,750.00 | | |
| 4/16/2018 | Mark A Velleca | Insider | Sell | 7,500 | $36.00 | $270,000.00 | | |
| 4/5/2018 | Jennifer K Moses | VP | Sell | 750 | $37.47 | $28,102.50 | | |
| 3/15/2018 | Rajesh Malik | Insider | Sell | 3,776 | $38.18 | $144,167.68 | | |
| 3/5/2018 | Jennifer K Moses | VP | Sell | 750 | $26.55 | $19,912.50 | | |
| 2/15/2018 | Rajesh Malik | Insider | Sell | 3,776 | $20.00 | $75,520.00 | | |
| 2/5/2018 | Jennifer K Moses | VP | Sell | 750 | $22.99 | $17,242.50 | | |
| 1/16/2018 | Rajesh Malik | Insider | Sell | 3,776 | $22.96 | $86,696.96 | | |
| 1/5/2018 | Jennifer K Moses | VP | Sell | 750 | $19.96 | $14,970.00 | | |
| 12/18/2017 | Mark A Velleca | Insider | Sell | 7,500 | $20.01 | $150,075.00 | | |
| 12/15/2017 | Medimmune Ventures, Inc. | Major Shareholder | Sell | 200,000 | $19.75 | $3,950,000.00 | | |
| 12/1/2017 | Medimmune Ventures, Inc. | Major Shareholder | Sell | 133,906 | $19.75 | $2,644,643.50 | | |
| 11/20/2017 | Medimmune Ventures, Inc. | Major Shareholder | Sell | 200,000 | $20.01 | $4,002,000.00 | | |
| 11/13/2017 | Fredric N Eshelman | Director | Buy | 250,000 | $19.73 | $4,932,500.00 | | |
| 5/22/2017 | Clay Thorp | Major Shareholder | Buy | 133,333 | $15.00 | $1,999,995.00 | | |
| 5/22/2017 | Fredric N Eshelman | Director | Buy | 300,000 | $15.00 | $4,500,000.00 | | |
| 5/22/2017 | Ra Capital Healthcare Fund Lp | Insider | Buy | 400,000 | $15.00 | $6,000,000.00 | | |
(Data available from 1/1/2013 forward)
G1 Therapeutics (NASDAQ GTHX) News Headlines
| Source: |
|
G1 Therapeutics (NASDAQ:GTHX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
G1 Therapeutics (NASDAQ:GTHX) Income Statement, Balance Sheet and Cash Flow Statement
G1 Therapeutics (NASDAQ GTHX) Stock Chart for Thursday, May, 24, 2018
Loading chart…
